BeiGene
BGNE
#939
Rank
โ‚น1.766 T
Marketcap
โ‚น15,744
Share price
-1.37%
Change (1 day)
1.15%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) Fails to deliver data

Key failure to deliver metrics for BeiGene :

A Failure to deliver also known as fails-to-deliver or FTD occurs when a buyer or seller is unable to meet his trading obligations. FTDs for US listed companies are reported to the SEC and published twice a month. Therefore there is a certain delay between the reporting and the publishing of the data.

Failures to deliver for BeiGene (BGNE) - 3 months history

Number of shares, 3 months chart

Biweekly Failures to deliver volume for BeiGene (BGNE) - since 2016

Volume in USD (price x number of shares), data since 2016

BeiGene (BGNE) Failure to deliver volume, Year over Year

Year Volume (Price x Shares) Change
2024โ‚น82.05 M97.54%
2023โ‚น41.54 M-57.94%
2022โ‚น98.76 M113.17%
2021โ‚น46.33 M-62.37%
2020โ‚น0.12 B40.02%
2019โ‚น87.92 M48.77%
2018โ‚น59.1 M255.99%
2017โ‚น16.6 M169.67%
2016โ‚น6.15 M

FTD volume in the last 3 months for similar companies or competitors

Company FTD volume (3 months) FTD volume (1 year) Country
โ‚น0.06 Mโ‚น0.41 M๐Ÿ‡บ๐Ÿ‡ธ USA
โ‚น6.17 Mโ‚น63.92 M๐Ÿ‡บ๐Ÿ‡ธ USA